Last reviewed · How we verify
NVP Healthcare — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
5 Phase 3
0 Phase 2
18 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| NVP-2203-R3 | NVP-2203-R3 | phase 3 | PD-1 inhibitor | PD-1 | Oncology | |
| NVP-2203-R1 | NVP-2203-R1 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| NVP-2203-R2 | NVP-2203-R2 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| NVP-1203-R | NVP-1203-R | phase 3 | PD-1 inhibitor | PD-1 | Oncology | |
| NVP-2203 | NVP-2203 | phase 3 | PD-1 inhibitor | PD-1 | Oncology |
Therapeutic area mix
- Oncology · 3
- Diabetes · 2
- Metabolic · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Beijing Tiantan Hospital · 2 shared drug classes
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 2 shared drug classes
- Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
- Asan Medical Center · 2 shared drug classes
- BioRay Pharmaceutical Co., Ltd. · 2 shared drug classes
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · 2 shared drug classes
- Addpharma Inc. · 2 shared drug classes
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for NVP Healthcare:
- NVP Healthcare pipeline updates — RSS
- NVP Healthcare pipeline updates — Atom
- NVP Healthcare pipeline updates — JSON
Cite this brief
Drug Landscape (2026). NVP Healthcare — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nvp-healthcare. Accessed 2026-05-17.